Chronic obstructive pulmonary disease complicating early-stage lung cancer

3^rd International Conference on Chronic Obstructive Pulmonary Disease

July 11-12, 2016 Brisbane, Australia

Ping Yang

Mayo Clinic College of Medicine, USA

Scientific Tracks Abstracts: J Pulm Respir Med

Abstract :

Chronic obstructive pulmonary disease (COPD) is present in 40-60% of Lung Cancer (LC) patients; some existed long before LC diagnosis and others were identifi ed at the time of LC diagnosis. Our clinical research team has been evaluating the impact of diff erent diagnostic time (prior vs. concurrent), severity of COPD and a subgroup of CT-defi ned emphysema on long-term survival of patients with early stage non-small cell lung cancer (NSCLC). Two patient cohorts include ~1400 NSCLC with known COPD status and ~1100 with known emphysema status. COPD was defi ned according to pulmonary function tests (post-bronchodilator FEV1/ FVC<0.70) or recorded medical diagnosis; severity was grouped by GOLD criteria (Global Initiative for Chronic Obstructive Lung Disease). Emphysema was based on standard-dose CT scan; percentage quantifi cation was determined through direct inspection and categorized into <5%, 6-24% and 25-60%. Five key fi ndings are summarized as follows: Patients with a prior COPD had a signifi cantly higher proportion of former smokers and moderate airfl ow obstruction than those with concurrent COPD. Worse survival was signifi cantly associated with prior COPD and moderate to severe airfl ow obstruction regardless of COPD diagnosis time. In surgically-treated patients, the overall postoperative complications were higher in patients with a greater emphysema score. Increasing emphysema score was signifi cantly associated with worse survival. More specifi c to resected LC in the predominant emphysematous region, patients with >6% emphysema experienced a mild decrease in FEV1 and an increase in FEV1/FVC. We conclude that COPD in general and emphysema in particular should be taken into careful consideration in LC treatment.

Biography :

Ping Yang has completed her MD from Beijing Medical College in China and PhD at Johns Hopkins University in USA. She has been leading a comprehensive lung cancer research program at Mayo Clinic since 1997, emphasizing patient-centered outcome research with COPD as one of the key interested areas. She has published more than 200 peer-reviewed papers and has been serving as an Editorial Board Member of Journal of Clinical Oncology and Associate Editor of Journal of Thoracic Oncology.

Email: Yang.Ping@mayo.edu